HC Wainwright Cuts LAVA Therapeutics (NASDAQ:LVTX) Price Target to $2.00

LAVA Therapeutics (NASDAQ:LVTX) had its price target decreased by HC Wainwright from $6.00 to $2.00 in a report issued on Friday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other research analysts have also recently commented on LVTX. JMP Securities reiterated a “market perform” rating and issued a $6.00 price target on shares of LAVA Therapeutics in a research note on Wednesday, December 11th. Citizens Jmp downgraded LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Leerink Partners restated a “market perform” rating and set a $2.00 price target (down from $11.00) on shares of LAVA Therapeutics in a report on Thursday, December 12th. Finally, Leerink Partnrs downgraded LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 12th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, LAVA Therapeutics has a consensus rating of “Hold” and a consensus target price of $3.33.

LAVA Therapeutics Price Performance

LVTX stock opened at $1.03 on Friday. LAVA Therapeutics has a 1 year low of $0.96 and a 1 year high of $6.47. The stock has a market cap of $26.11 million, a price-to-earnings ratio of -1.00 and a beta of 0.43. The company has a 50 day simple moving average of $1.62 and a 200 day simple moving average of $1.78.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new stake in shares of LAVA Therapeutics in the third quarter valued at about $32,000. XTX Topco Ltd acquired a new stake in LAVA Therapeutics during the 2nd quarter valued at approximately $55,000. Finally, Pathway Financial Advisors LLC increased its position in LAVA Therapeutics by 70.8% during the 3rd quarter. Pathway Financial Advisors LLC now owns 102,500 shares of the company’s stock valued at $170,000 after purchasing an additional 42,500 shares during the period.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.